This module uses fundamental data of Carmell Therapeutics to approximate its Piotroski F score. Carmell Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Carmell Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Carmell Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Carmell Therapeutics Altman Z Score, Carmell Therapeutics Correlation, Carmell Therapeutics Valuation, as well as analyze Carmell Therapeutics Alpha and Beta and Carmell Therapeutics Hype Analysis.
At this time, Carmell Therapeutics' Net Debt To EBITDA is fairly stable compared to the past year. Debt To Equity is likely to climb to 0.08 in 2025, despite the fact that Net Debt is likely to grow to (663.5 K). At this time, Carmell Therapeutics' Debt To Equity is fairly stable compared to the past year. Capex Per Share is likely to climb to 0 in 2025, despite the fact that Operating Cash Flow Per Share is likely to grow to (0.83).
At this time, it appears that Carmell Therapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Carmell Therapeutics is to make sure Carmell is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Carmell Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Carmell Therapeutics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Carmell Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Carmell Therapeutics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
2.12
At this time, Carmell Therapeutics' Book Value Per Share is fairly stable compared to the past year.
About Carmell Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Carmell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carmell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carmell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.